Introduction {#s1}
============

The contribution of anti-HER2 therapies to the management of HER2-positive breast cancer patients is undeniable both in metastatic and adjuvant settings ([@B1]--[@B6]). In the same way, significant benefit was observed with neoadjuvant trastuzumab treatment, obtaining pathological complete response (pCR) rates from 25 to 46% ([@B7]--[@B12]). These results were improved with the use of pertuzumab combined with trastuzumab, reaching pCR rates between 49 and 69% ([@B8], [@B13]--[@B17]).

Several authors have shown that all four intrinsic subtypes can be found in clinically HER2+ tumors. Although the majority of cases are HER2 enriched (40--72%), luminal A (10--27%), luminal B (10--28%), and basal-like tumors (7--14%) are also represented ([@B13], [@B17]--[@B24]). This distribution may vary depending on the hormone receptor status. In the hormone-receptor-negative subset, the main intrinsic subtype was HER2 enriched (51--85%), with fewer cases of luminal (luminal A 0.7--24%; luminal B 3--11%), and basal-like subtypes (9--28%) ([@B12], [@B19], [@B20], [@B22], [@B24], [@B25]). In contrast, in hormone-receptor-positive tumors, luminal subtypes were more frequent (luminal A 28--44%; luminal B 24--48%) than HER2-enriched (8--32%) or basal-like (0.5--2.5%) ones ([@B12], [@B20], [@B22], [@B25], [@B26]).

This heterogeneity is also reflected in the magnitude of the benefit of neoadjuvant anti-HER2 therapies. In the NOAH trial, pCR rate obtained in the trastuzumab arm was higher in the HER2-enriched subtype and in tumors with high ROR scores ([@B18]). This association was also observed in patients treated with double HER2 blockade (i.e., trastuzumab plus lapatinib or trastuzumab plus pertuzumab) plus chemotherapy. Neoadjuvant trastuzumab with or without lapatinib shows pCR rates of 50--70% in HER2-enriched tumors, 9--34% in luminal A, 17--36% in luminal B, and 25--38% in basal-like cases ([@B12], [@B25], [@B27]). Similarly, pCR rates by intrinsic subtype in patients treated with neoadjuvant pertuzumab plus trastuzumab were 70--83% in the HER2-enriched subtype, 16--45% in luminal A, 16--52% in luminal B, and 20--85% in basal-like tumors ([@B13], [@B17], [@B22], [@B23]). In a series of patients with BluePrint-defined subtypes, the pCR rate was 76% in the HER2+ type, 31% in the luminal type, and 43% in the basal type ([@B28]).

The aim of this work was to evaluate whether the effect of neoadjuvant pertuzumab combined with trastuzumab in comparison with trastuzumab alone varies as a function of PAM50-defined intrinsic subtypes in a real-world cohort of patients with HER2-positive early breast cancer.

Materials and Methods {#s2}
=====================

Patients
--------

A total of 254 patients with HER2+ early breast cancer consecutively treated with standard neoadjuvant chemotherapy (NAC) in eight Spanish hospitals were included in the study. The whole population was divided in two cohorts: Cohort A received trastuzumab plus NAC, and Cohort B was treated with pertuzumab and trastuzumab plus NAC. Standard NAC included taxanes with or without anthracyclines. Adjuvant radiotherapy was performed according local practice. Adjuvant endocrine therapy was administered in all hormone-receptor-positive patients.

Patient data were derived from the patients\' clinical records and original pathology reports. Although the analysis was retrospective, the data were collected prospectively.

The study was approved by local ethics committees. Written informed consent was obtained from each participant.

Definition of pCR, Hormone Receptor, HER2 Status, Immunohistochemical Phenotype, and Intrinsic Subtype
------------------------------------------------------------------------------------------------------

pCR was defined as the complete disappearance of invasive tumor cells (ypT0 or ypTis and ypN0). All pathological determinations were performed on diagnostic biopsies. Tumors were classified as estrogen-receptor and progesterone-receptor-positive if ≥1% of tumor cells were stained. HER2+ status was defined by an immunohistochemistry score of 3+ or a HER2 amplification ratio of 2.0 or more by FISH or SISH. Hormone-receptor-positive cases were classified as Luminal-HER2 (luminal immunophenotype) and those with negative hormone receptors such ones as HER2+ (HER2+ immunophenotype).

Assignment of the intrinsic subtype was realized using the research-based PAM50 signature as previously described ([@B29]) in order to categorize all cases as one of the following subtypes: luminal A, luminal B, HER2-enriched, basal-like, and normal-like.

Statistical Analysis
--------------------

Associations between variables and pCR were evaluated by the chi-squared test or Fisher\'s exact test. Multivariate logistic regression analyses were used to evaluate the association of each intrinsic subtype with pCR and included the variables that showed significant associations in univariate analyses. Cases with unknown data for any of the variables considered were excluded from multivariate analyses.

All the tests were two-sided, and a *P*-value of \< 0.05 was considered to indicate statistical significance. Analyses were carried out using the R system for statistical computing (version 3.5.2).

Results {#s3}
=======

Patients\' Characteristics
--------------------------

A total of 254 patients were included in the study: 132 patients were treated with NAC plus trastuzumab (Cohort A) and 122 patients with NAC plus pertuzumab and trastuzumab (Cohort B). The clinical characteristics are outlined in [Table 1](#T1){ref-type="table"}. There were more cases with a greater tumor burden in Cohort B than in Cohort A (T3 or T4 tumor size: 33 vs. 19%; stage I: 1 vs. 14%). Slightly more patients were treated with taxanes alone in Cohort B (14 vs. 7%).

###### 

Patient characteristics.

                                                             **Cohort A (T)**   **Cohort B (P+T)**         
  ---------------------------------------------------------- ------------------ -------------------- ----- -----
  **Total**                                                  132                122                        
  **Menopausal status**                                                                                    
  Premenopausal                                              57                 43%                  57    47%
  Postmenopausal                                             50                 38%                  52    43%
  NA                                                         25                 19%                  13    11%
  **Age**                                                                                                  
  \<50                                                       63                 48%                  58    48%
  ≥50                                                        69                 52%                  64    52%
  **Tumor size**                                                                                           
  T1                                                         26                 20%                  14    11%
  T2                                                         78                 59%                  67    55%
  T3                                                         15                 11%                  27    22%
  T4                                                         10                 8%                   13    11%
  NA                                                         3                  2%                   1     1%
  **Nodal status**                                                                                         
  Negative                                                   55                 42%                  44    36%
  Positive                                                   77                 58%                  77    63%
  NA                                                                                                 1     1%
  **Stage**                                                                                                
  I                                                          18                 14%                  1     1%
  II                                                         90                 68%                  90    74%
  III                                                        21                 16%                  30    25%
  NA                                                         3                  2%                   1     1%
  **Grade**                                                                                                
  1--2                                                       62                 47%                  37    30%
  3                                                          45                 34%                  45    37%
  ND                                                         25                 19%                  40    33%
  **Hormone receptor**                                                                                     
  Negative                                                   41                 31%                  48    39%
  Positive                                                   91                 69%                  74    61%
  **Ki67**                                                                                                 
  \<20                                                       25                 19%                  13    11%
  20--50                                                     44                 33%                  76    62%
  \>50                                                       29                 22%                  30    25%
  ND                                                         34                 26%                  3     2%
  **NAC**                                                                                                  
  Taxanes[^a^](#TN1){ref-type="table-fn"}                    9                  7%                   17    14%
  Taxanes + Anthracyclines[^b^](#TN2){ref-type="table-fn"}   123                93%                  105   86%
  **pCR**                                                                                                  
  No                                                         80                 61%                  48    39%
  Yes                                                        52                 39%                  74    61%
  **Immunohistochemical phenotype**                                                                        
  Luminal-HER2                                               91                 69%                  74    61%
  HER2                                                       41                 31%                  48    39%
  **PAM50-based subtype**                                                                                  
  Luminal A                                                  16                 12%                  17    14%
  Luminal B                                                  19                 14%                  22    18%
  HER2-enriched                                              92                 70%                  68    56%
  Basal-like                                                 2                  2%                   15    12%
  Normal                                                     3                  2%                         

*NA, Not available*.

*Paclitaxel-Trastuzumab; Docetaxel-Trastuzumab; Paclitaxel-Trastuzumab-Pertuzumab; Docetaxel-Trastuzumab-Pertuzumab*.

*Epirrubicin-Cyclophosphamide followed by Docetaxel-Trastuzumab; Epirrubicin-Cyclophosphamide followed by Paclitaxel-Trastuzumab; Adriamycin-Cyclophosphamide followed by Docetaxel-Trastuzumab; Adriamycin-Cyclophosphamide followed by Paclitaxel-Trastuzumab; Fluorouracil-Epirrubicin-Cyclophosphamide followed by Docetaxel-Trastuzumab; Fluorouracil-Epirrubicin-Cyclophosphamide followed by Paclitaxel-Trastuzumab; Epirrubicin-Cyclophosphamide followed by Docetaxel-Trastuzumab-Pertuzumab; Epirrubicin-Cyclophosphamide followed by Paclitaxel-Trastuzumab-Pertuzumab; Adriamycin-Cyclophosphamide followed by Docetaxel-Trastuzumab-Pertuzumab; Adriamycin-Cyclophosphamide followed by Paclitaxel-Trastuzumab-Pertuzumab; Fluorouracil-Epirrubicin-Cyclophosphamide followed by Docetaxel-Trastuzumab-Pertuzumab; Fluorouracil-Epirrubicin-Cyclophosphamide followed by Paclitaxel-Trastuzumab-Pertuzumab*.

The overall pCR rate was 39% in Cohort A and 61% in Cohort B. The immunohistochemical phenotype distribution was similar in both cohorts: luminal-HER2 69 vs. 61% and HER2+ cases 31 vs. 39%. Regarding PAM50-assigned subtypes, there were more HER2-enriched tumors in Cohort A (70 vs. 56%) and more basal-like tumors in Cohort B (12 vs. 2%), with similar luminal case distributions (luminal A 12 vs. 14%; luminal B 14 vs. 18%).

Association Between Variables and pCR
-------------------------------------

In the whole population [(Table 2)](#T2){ref-type="table"}, pCR was significantly related to the type of treatment (Cohort A 39.4% vs. Cohort B 60.6%; *P* = 0.0011), histological grade (grade 1 + 2 35.5% vs. grade 3 62.2%; *P* = 0.0007), Ki67 level (\<20% 28.9% vs. 20--50% 60.8% vs. \>50% 54.2%; *P* = 0.003), immunohistochemical phenotype (luminal HER2 38.7% vs. HER2+ 69.6%; *P* = 0.000005), and PAM50-based subtype (luminal A 21.2% vs. luminal B 31.7% vs. HER-2 enriched 60% vs. basal like 52.9%; *P* = 0.0004). Similar results were observed in separate analyses of each cohort [(Table 2)](#T2){ref-type="table"}.

###### 

Association between variables and pCR.

                 **Whole population**   **Cohort A (T)**   **Cohort B (P+T)**                   
  -------------- ---------------------- ------------------ -------------------- -------- ------ -------
  Cohort A       39.4                   0.001                                                   
  Cohort B       60.6                                                                           
  Grade 1--2     35.5                   0.00007            27.4                 0.038    40.5   0.002
  Grade 3        62.2                                      48.9                          75.5   
  Ki67 \<20%     28.9                   0.002              20.0                 0.006    46.1   0.4
  Ki67 20--50%   60.8                                      56.8                          63.1   
  Ki67 \>50%     54.2                                      41.3                          66.0   
  Luminal-HER2   38.7                   0.000005           30.7                 0.004    48.6   0.001
  HER2           69.6                                      58.5                          79.1   
  Luminal A      21.2                   0.00004            6.2                  0.0004   35.2   0.007
  Luminal B      31.7                                      15.7                          45.4   
  HER2-E         60.0                                      50.0                          73.5   
  Basal-like     52.9                                      50.0                          53.3   
  Normal         33.3                                      33.3                          0.0    

The better results found in cohort B in the whole population were also observed in an evaluation of different subpopulations [(Table 3)](#T3){ref-type="table"}. Thus, immunohistochemical luminal tumors showed greater pCR with pertuzumab and trastuzumab treatment (48.6 vs. 30.8%; *P* = 0.03) and also HER2+ patients (58.5 vs. 79.6%; *P* = 0.06). In addition, in the luminal PAM50-based subtype, a pCR rate of 11.4% was obtained with trastuzumab treatment vs. 41% with combination treatment (*P* = 0.008) and in the HER2-enriched subtype, these rates were 50 vs. 73.5% (*P* = 0.004).

###### 

Association between variables and pCR in specific subpopulations.

                                     **pCR (%)**   ***P***
  ---------------------------------- ------------- ---------
  **Luminal-HER2 immunophenotype**                 
  Cohort A                           30.8          0.03
  Cohort B                           48.6          
  **HER2+** **immunophenotype**                    
  Cohort A                           58.5          0.06
  Cohort B                           79.6          
  **Luminal PAM50 subtypes**                       
  Cohort A                           11.4          0.008
  Cohort B                           41.0          
  **HER2-enriched PAM50 subtypes**                 
  Cohort A                           50.0          0.004
  Cohort B                           73.5          

Multivariate Analyses
---------------------

The variables that remained significantly associated with pCR in the whole population were treatment Cohort B \[Odds Ratio (OR) 2.5; 95% CI 1.07--6; *P* = 0.036\], histological grade 3 (OR 3.41; 95% CI 14.48--8.09; *P* = 0.004), immunophenotype HER2+ (OR 3.82; 95% CI 1.39--11.6; *P* = 0.01), and PAM50-based HER2-enriched subtype (OR 2.98; 95% CI 1.39--11.6; *P* = 0.02) [(Table 4)](#T4){ref-type="table"}.

###### 

Multivariate logistic regression of pCR.

             **Whole population**   **Cohort A (T)**   **Cohort B (P+T)**   **Luminal PAM50**   **HER2-E PAM50**                                                                               
  ---------- ---------------------- ------------------ -------------------- ------------------- ------------------ ------ ----- ----------- ------ ----- ------------ ------ ----- ----------- -------
  Cohort B   2.5                    1.07--6.00         0.03                 --                  --                 --     --    --          --     4.2   1.05--22.4   0.05   2.7   1.01--7.6   0.05
  Grade 3    3.41                   1.48--8.09         0.004                5.1                 1.5--20.7          0.01   3.4   1.1--10.8   0.03   4.5   1.1--19.0    0.03   4.1   1.6--11.2   0.003
  HER2ihc    3.82                   1.39--11.6         0.01                 9.8                 2.0--75.3          0.01   --    --          --     --    --           --     --    --          --
  HER2-E     2.98                   1.19--7.7          0.02                 --                  --                 --     3.7   1.2--11     0.02   --    --           --     --    --          --

*OR, odds ratio; CI, Confidence Interval; HER2ihc, immunophenotype HER2; HER2E, HER2 enriched*.

In the cohort of patients treated with trastuzumab alone, grade 3 (OR 5.1; 95% CI 1.5--20.7; *P* = 0.01) and immunophenotype HER2+ (OR 9.8; 95% CI 2.0--75.3; *P* = 0.01) were the only variables independently associated with a higher probability of pCR, and in the cohort of patients that received pertuzumab and trastuzumab, these variables were grade 3 (OR 3.4; 95% CI 1.1--10.8; *P* = 0.03) and PAM50-based HER2-enriched subtype (OR 3.7; 95% CI 1.2--11; *P* = 0.02) [(Table 4)](#T4){ref-type="table"}.

In an analysis of luminal PAM50-based tumors, the variables that remained significantly associated with pCR were treatment Cohort B (OR 4.2; 95% CI 1.05--22.4; *P* = 0.05), and grade 3 (OR 4.5; 95% CI 1.1--19.0; *P* = 0.03); this was also true in the HER2-enriched subgroup (Cohort B OR 2.7; 95% CI 1.01--7.6; *P* = 0.05. Grade 3 OR 4.1; 95% CI 1.6--11.2; *P* = 0.003) [(Table 4)](#T4){ref-type="table"}.

Discussion {#s4}
==========

Our study provides valuable information from the real world about neoadjuvant anti-HER2 treatment in early breast cancer, showing that the rate of pCR obtained by double blockade with pertuzumab plus trastuzumab exceeds by 20% that obtained with trastuzumab alone. The pCR rate observed in our series with pertuzumab and trastuzumab treatment (60.6%) is in the range of responses observed in the published phase II-III trials (45.8--69.8%) ([@B8], [@B13]--[@B15], [@B17], [@B22]). Moreover, the pCR rate found in patients treated with trastuzumab alone (39.4%) is in agreement with previous data (31--46%) ([@B7]--[@B12]). Interestingly, the greater efficacy shown by the combination of pertuzumab and trastuzumab in our study was despite the fact that the patients in this cohort had worse prognostic characteristics than those who received trastuzumab alone, with a higher percentage of tumors larger than 5 cm or a greater number of cases with nodal involvement. Lower pCR rates were observed in patients with the luminal immunophenotype in both the cohort treated with pertuzumab and trastuzumab and in the one receiving trastuzumab alone. This finding is consistent with previously published data ([@B8], [@B9], [@B12], [@B15], [@B17], [@B28]).

Although most tumors positive for HER2 by immunohistochemistry or by *in situ* hybridization correspond to the intrinsic HER2-enriched subtype, it is possible to identify any of the remaining intrinsic subtypes in this type of tumor ([@B19], [@B29], [@B30]). Surprisingly, the percentage of cases by intrinsic subtype in our two patient cohorts differ to some extent, despite the fact that the processing of the tumor samples was performed in the same laboratory, albeit at different times. In the group of patients treated with pertuzumab and trastuzumab, 56% of the cases corresponded to the HER2-enriched, 14% to the luminal A, 18% to the luminal B, and 12% to the basal-like subtype, and this distribution is in agreement with previously published data ([@B13], [@B17], [@B18], [@B20], [@B22], [@B23]). However, in the cohort of patients who received trastuzumab alone, there was a higher percentage of HER2-enriched cases (70%), a lower number of basal-like tumors (2%), and a similar amount of luminal tumors (luminal A 12%; luminal B 14%). Similar data were reported by Perez et al. from NCCTG N9831 Trial ([@B21]) and more recently by Tolaney et al. from the APT Trial ([@B24]).

Anti-HER2 therapies are more beneficial in HER2-enriched tumors, but all intrinsic subtypes benefit from this type of treatment in both the adjuvant ([@B20], [@B21]) and neoadjuvant settings, and the HER2-enriched subtype benefits the most ([@B13], [@B17], [@B18], [@B22], [@B23], [@B28]). According to these data, our patients with HER2-enriched tumors obtained the highest pCR rate with both treatment schedules. Furthermore, the use of pertuzumab and trastuzumab was the only variable, together with the histological grade, that provided independent predictive information for pCR events in both HER2-enriched tumors (OR 2.7) and patients with luminal subtypes (OR 4.2). Although the number of patients was small, the basal-like subtype shows no benefit with the use of anti-HER2 therapy, achieving nearly the same pCR rate with pertuzumab and trastuzumab as with trastuzumab alone.

To our knowledge, there is no published series of real-world patients with early HER2+ breast cancer treated with NAC plus pertuzumab and trastuzumab or trastuzumab alone, in which the intrinsic subtypes have been established according to the PAM50 definition and their relationship with the pCR rate analyzed. Beitsch et al. ([@B28]) published data from patients included in a prospective registry, of whom 178 were treated with NAC plus trastuzumab and 119 with NAC plus pertuzumab and trastuzumab and in which the molecular subtype was defined by BluePrint platform. Their results agree with ours, showing a higher response with double HER2 blockade vs. treatment with trastuzumab alone in the HER2+ type (76% vs. 57%) and the luminal type (31% vs. 8%) and no differences in the basal type (43% vs. 45%). Recently, Fashing et al. ([@B31]) published their results from a series of patients included in an ongoing registry comparing two cohorts of patients that received neoadjuvant treatment with chemotherapy plus trastuzumab or chemotherapy plus trastuzumab and pertuzumab. In agreement with our results, there was a greater number of pCR in patients treated with pertuzumab plus trastuzumab with an adjusted OR for double HER2 blockade vs. trastuzumab alone of 2.04 (95% CI 1.24--3.35).

Our results confirm the data obtained from clinical trials in patients treated in clinical practice, showing that the addition of pertuzumab to trastuzumab and neoadjuvant chemotherapy increase the pCR rate substantially, especially in the HER2-enriched subtype but also in luminal subtypes, with no apparent benefit in basal-like tumors.
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